Gastrointestinal toxicity remains one of the foremost challenges in clinical pharmacology, often limiting therapeutic options due to harsh side effects on the digestive system. The intestinal epithelium, a single-cell-layered barrier, orchestrates the selective permeability necessary for nutrient absorption while simultaneously acting as a sentinel against harmful pathogens and toxins. Traditionally, the focus has been on chemical interactions and inflammatory responses that drugs provoke. However, this new research shifts the spotlight towards the cytoskeletal dynamics within epithelial cells, offering a nuanced perspective that bridges cellular biology and pharmacotoxicology.

Central to this frontier research is the human intestinal epithelium model used by the researchers, which closely mirrors the physiological and functional characteristics of the native human gut lining. This model provides an unparalleled platform to observe drug-induced perturbations in a lab setting that is clinically relevant. By utilizing this approach, the team captured how drugs can elicit cytoskeletal remodeling that undermines tight junctions—protein complexes responsible for maintaining the selective permeability of the epithelium. The disruption of these tight junctions paves the way for increased intestinal permeability, often termed “leaky gut,” linking drug exposure directly to compromised barrier function.

The cytoskeleton, an intricate network of filamentous proteins, governs the morphology, mechanical resilience, and intracellular transport within epithelial cells. The study reveals that exposure to specific pharmaceutical compounds instigates cytoskeletal alterations that result in destabilization and mislocalization of crucial tight junction proteins such as occludin and claudins. This discovery elucidates how drugs inadvertently trigger downstream signaling cascades that remodel the cellular architecture, ultimately breaking down the epithelial barrier’s integrity with potentially severe clinical consequences.

Interestingly, the research highlights that not all drugs exert uniform effects on the cytoskeleton and barrier function, emphasizing a drug-specific profile of toxicity. This heterogeneity points toward a complex interaction network where certain chemical properties or molecular targets of drugs might predispose them to induce cytoskeletal stress. Understanding these nuances opens new avenues for personalized medicine strategies, whereby drug formulations or dosing regimens can be optimized to minimize adverse effects on the gut barrier while preserving therapeutic efficacy.

Moreover, the researchers detailed the signaling pathways implicated in these cytoskeleton-mediated disturbances. For instance, molecules involved in actin filament organization and cellular adhesion were particularly dysregulated upon drug treatment, suggesting that targeted modulation of these pathways could be a strategic approach to safeguard barrier integrity. This could propel the development of adjunct therapies that co-administer cytoskeleton-stabilizing agents alongside potentially harmful drugs to preemptively counteract gastrointestinal toxicity.

The implications of this study extend beyond merely elucidating mechanisms; they cast a practical light on drug development pipelines and clinical patient management. By incorporating assays that evaluate cytoskeletal impact and barrier function into preclinical screening, pharmaceutical companies could better predict gastrointestinal side effects before advancing drugs to costly human trials. Clinicians, too, might benefit from biomarkers linked to cytoskeletal disruption to monitor patients at risk and tailor interventions accordingly.

Furthermore, the discovery that the cytoskeleton is at the nexus of drug-induced epithelial dysfunction resonates with emerging concepts in gut health and systemic disease. Increased intestinal permeability is not only a hallmark of gastrointestinal disorders but is also implicated in systemic inflammation, metabolic diseases, and even neurodegenerative conditions. Thus, preserving the cytoskeletal integrity of the intestinal epithelium may offer therapeutic dividends that transcend the gut, underscoring the systemic significance of these findings.

The study also emphasizes the importance of utilizing clinically relevant human cell models over animal models, which often fail to replicate human-specific responses adequately. The ability to recapitulate the human intestinal environment in vitro enhances translational potential and accelerates drug safety evaluations. This approach aligns with the broader scientific movement toward organ-on-a-chip and tissue engineering technologies that strive to mirror human physiology with greater fidelity.

As science continues to unravel the complexities of drug interactions at the cellular level, the insights illuminated here herald a paradigm shift. Far from being passive bystanders, cytoskeletal components emerge as dynamic mediators that dictate the fate of epithelial barrier function under pharmacological stress. This acknowledgment encourages a multidisciplinary strategy, integrating cell biology, pharmacology, and bioengineering to mitigate adverse drug reactions.

Looking forward, the research team suggests that future studies should investigate the reversibility of cytoskeleton-induced barrier disruptions and explore how chronic drug exposure influences epithelial homeostasis over time. Unraveling these temporal dynamics will be crucial in designing interventions that not only prevent immediate toxicity but also shield the epithelium from long-term structural damage.

In conclusion, this pioneering research offers a compelling narrative that connects drug-induced gastrointestinal toxicity with cytoskeletal impairment at the cellular frontier. By illuminating the pathways through which drugs compromise epithelial barrier integrity, the study sets the stage for innovative therapeutic strategies and safer drug design. As the pharmaceutical landscape grapples with balancing efficacy and safety, these revelations provide a beacon for reducing gastrointestinal adverse effects, thereby improving patient outcomes worldwide.

Subject of Research: Drug-induced gastrointestinal toxicity and the impact on intestinal epithelial barrier integrity mediated by cytoskeletal dynamics.

Article Title: Drug-induced gastrointestinal toxicity and barrier integrity: cytoskeleton-mediated impairment in a clinically relevant human intestinal epithelium model.

Article References:
Yu, W.D., Lee, S., Cho, HS. et al. Drug-induced gastrointestinal toxicity and barrier integrity: cytoskeleton-mediated impairment in a clinically relevant human intestinal epithelium model. Exp Mol Med (2026). https://doi.org/10.1038/s12276-025-01635-6

Image Credits: AI Generated

DOI: 12 February 2026

At its core, cell movement has always been modeled assuming positive viscosity—a drag force that inherently resists motion, akin to pushing through a fluid like honey or oil. Viscosity, a measure of a substance’s resistance to flow or deformation, generally acts as a dissipative factor slowing motion. For decades, scientists accepted that within cellular assemblies, this viscosity would impede the ability of cells to migrate collectively, particularly in tightly packed epithelial layers essential for forming barriers and repairing tissue. However, the latest research led by Associate Professor Jacob Notbohm and PhD candidate Molly McCord has turned this assumption on its head by demonstrating that, in certain conditions, cellular collectives generate negative viscosity.

The team’s pioneering methodology involved an innovative combination of optical imaging and mechanical analysis. By observing how monocultures of epithelial cells deformed an underlying compliant gel substrate as they migrated, they were able to quantify the forces these cells exerted on their environment with unprecedented spatial resolution. Beyond just cataloging force magnitudes, McCord developed an advanced analytical framework to dissect viscosity values not only at the cellular level but across multicellular regions within the monolayer. Unexpectedly, areas emerged where viscosity values dipped below zero—a hallmark of negative viscosity suggesting that instead of resisting motion, these cells actively contributed energy to propel collective movement.

To conceptualize this phenomenon, Notbohm draws an analogy to driving a car: “Imagine a vehicle moving through air, which normally provides drag, slowing it down. Negative viscosity would be like the air instead pushing the car forward, adding energy rather than removing it.” While initially counterintuitive and seemingly contradictory to foundational physical laws, negative viscosity is permissible in active biological systems that continuously transduce chemical energy into mechanical work. The cells, powered by metabolic processes converting nutrients into usable energy, can therefore exhibit complex mechanical behaviors not seen in passive materials.

Delving deeper, the researchers correlated regions of negative viscosity with heightened metabolic activity, underscoring the biological underpinnings of this mechanical anomaly. Cells in these zones exhibited elevated energy consumption, reflecting a biochemical state primed to generate motion-enhancing forces within the cellular collective. This discovery elegantly links cellular energetics with emergent mechanical properties, suggesting a coordinated interplay where bioenergetics directly modulates the physical characteristics of tissue motion. Such insights provide a fresh framework to reevaluate how cellular systems integrate metabolic cues with mechanical outputs.

The ramifications of uncovering negative viscosity stretch beyond basic science, offering transformative possibilities for medical and bioengineering disciplines. Wound healing, an inherently collective cellular process requiring coordinated migration to restore tissue integrity, may be influenced by modulating these viscous properties. Accelerating or directing collective movement by harnessing or mimicking negative viscosity mechanisms could pave the way for therapies that improve recovery outcomes and reduce chronic wound complications.

Similarly, the findings may illuminate key processes in embryonic development and tissue morphogenesis, where precise cell group movements sculpt form and function. Understanding the mechanical language of cells operating under negative viscosity could unravel developmental pathologies and offer avenues to engineer tissues with enhanced regenerative capabilities. By integrating these mechanical principles into computational models, researchers can predict and potentially control how cells behave within complex multicellular systems.

Furthermore, the study breaks ground on quantifying a parameter that had eluded direct measurement—effective viscosity within cell monolayers. Prior attempts to model collective cell motion often lacked empirical measures of viscous resistance, limiting predictive accuracy. McCord and Notbohm’s experimental approach fills this critical gap, providing a robust platform for future investigations on cellular mechanics. This quantitative advance enables refinement of biophysical models, enhancing understanding of force generation, tissue rheology, and mechanotransduction.

The implications of negative viscosity extend to the realm of active matter physics, where biological systems are viewed through the lens of nonequilibrium thermodynamics. Cells, as active materials, convert stored energy into mechanical work, displaying properties unattainable in inanimate matter at equilibrium. Demonstrating negative viscosity in epithelial monolayers not only supports active matter theories but encourages cross-disciplinary dialogues bridging biology, physics, and engineering.

While the discovery is compelling, the research community acknowledges that much remains to be explored. How widespread is negative viscosity among different cell types and tissues? What molecular mechanisms govern the transition from positive to negative viscosity states? Can external factors such as biochemical signals or mechanical constraints modulate this property? Addressing these questions will deepen mechanistic insights and unlock new frontiers in cellular biomechanics.

The research, funded by the National Science Foundation and the National Institutes of Health, exemplifies how interdisciplinary collaboration enhances innovation. By combining experimental mechanics, advanced imaging, and biological analysis, the team achieved a synthesis of quantitative rigor and physiological relevance that sets new standards in the field.

In conclusion, the identification of negative viscosity within epithelial cell collectives marks a paradigm shift in our comprehension of cellular motion. It challenges prevailing assumptions and opens avenues that span from fundamental science to applied medicine. As this novel concept gains momentum, it promises to reshape the landscape of cellular biomechanics and inspire inventive strategies to manipulate tissue dynamics for health and disease.

Subject of Research: Cells

Article Title: Energy Injection in an Epithelial Cell Monolayer Indicated by Negative Viscosity

News Publication Date: 4-Dec-2025

Web References: https://journals.aps.org/prxlife/abstract/10.1103/9lnm-gm3j

References: Not specified beyond the journal article.

Image Credits: Joel Hallberg / UW–Madison

Keywords

Cells, Cell Biology, Biomechanics, Negative Viscosity, Epithelial Cells, Collective Cell Migration, Active Matter, Tissue Mechanics, Wound Healing, Cell Metabolism, Biophysics, Tissue Development